SUVEN LIFE SCIENCES LTD							
Regd. Off: Serene Chambers, Road No.5, Banjara Hills, Hyderabad - 500 034 UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th Jun 2013 PART - I							
PART -		TER ENDED 30th	Jun 2013		Rs. in Lakhs		
		Quarter Ended			Previous Year Ended		
SI. No.	PARTICULARS	30/06/2013	31/03/2013	30/06/2012	31/03/2013		
		Un-Audited	Un-audited	Un-audited	Audited		
1	Income from operations						
	(a) Net sales/income from operations (Net of excise duty)	10,866.96	7,470.36	7,052.72	25,788.46		
	(b) Other operating income	-	-	-	-		
•	Total income from operations (net)	10,866.96	7,470.36	7,052.72	25,788.46		
2	Expenses	3,374.55	2,634.47	2,144.63	8,827.40		
	a) Cost of materials consumed b) Purchases of stock-in-trade	5,574.55	2,034.47	2,144.03	0,027.40		
		-	-	-	(550 (0)		
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	14.69	185.25	330.84	(559.63)		
	 d) Employee benefits expense e) Depreciation and amortisation expense 	779.83 209.48	554.62 214.43	651.73 183.23	2,537.70 786.72		
	f) Other expenses - Manufacturing Exps	1,159.51	1,147.76	848.55	3,904.81		
	- Selling Exps	1,139.31	223.65	100.21	502.80		
	- Administrative Exps	332.38	409.34	517.42	1,787.50		
	- R & D Exps	793.87	982.12	874.68	3,469.32		
	- Provision for MTM on Forward contracts	(1.53)	(26.07)	250.96	-		
	Total expenses	6,773.25	6,325.57	5,902.25	21,256.62		
3	Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	4,093.71	1,144.79	1,150.47	4,531.84		
4	Other Income	315.53	54.29	52.47	104.34		
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 ± 4)	4,409.24	1,199.08	1,202.94	4,636.18		
6	Finance costs	319.06	270.74	321.92	1,350.94		
7	Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5 \pm 6)	4,090.18	928.34	881.02	3,285.24		
8	Exceptional Items Profit/Loss from Ordinary Activities before tax (7 ± 8)	- 4,090.18	- 928.34	- 881.02	-		
9 10	Tax Expenses	4,090.18	928.34 65.30	84.68	3,285.24 201.29		
11	Net Profit/ (Loss) from Ordinary Activities after tax (9 ± 10)	2,977.19	863.04	796.34	3,083.95		
12	Extraordinary Items (net of tax expense ₹ Lakhs)	-	-	-	-		
13	Net Profit (+)/Loss(-) for the period (11 ± 12)	2,977.19	863.04	796.34	3,083.95		
14	Share of profit / (loss) of associates*	-	-	-	-		
15	Minority interest *	-	-	-	-		
16	Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13 \pm 14 \pm 15) *	-	-	-	-		
17	Paid-up equity share capital	1,168.29	1,168.29	1,167.32	1,168.29		
	(Face Value of the Share shall be indicated)	Re.1.00	Re.1.00	Re.1.00	Re.1.00		
18	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting vear				14,277.70		
19.i	Earning Per Share (EPS) (before extraordinary items) (of ₹ Rs.1/- each) (not annualised):						
	a) Basic	2.55	0.74	0.68	2.64		
	b) Diluted	2.55	0.74	0.68	2.64		
19.ii	Earning Per Share (EPS) (after extraordinary items) (of Rs.1/- each) (not annualised):	0.5-		0.45			
	a) Basic	2.55	0.74	0.68	2.64		
	b) Diluted	2.55	0.74	0.68	2.64		

Going beyond Commitment,

PART -	PART - II						
		30/06/2013	31/03/2013	30/06/2012	31/03/2013		
А	PARTICULARS OF SHAREHOLDING	Un-Audited	Un-audited	Un-audited	Audited		
1	Public share holdings						
	- Number of shares	41,171,212	41,993,960	42,679,160	41,993,960		
	- Percentage of Share holding	35.24%	35.94%	36.56%	35.94%		
2	Promoters and promoter group Shareholding**						
	a) Pledged / Encumbered	NIL	NIL	NIL	NIL		
	- Number of shares						
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter	NIL	NIL	NIL	NIL		
	group)						
	 Percentage of shares (as a % of the total share capital of the company) 	NIL	NIL	NIL	NIL		
	b) Non-Encumbered	75,657,576	74,834,828	74,052,828	74,834,828		
	- Number of shares						
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter	100.00%	100.00%	100.00%	100.00%		
	group)						
	 Percentage of shares (as a % of the total share capital of the company) 	64.76%	64.06%	63.44%	64.06%		
	Particulars	3 months ended (30/06/2013)					
В	INVESTOR COMPLAINTS						
	Pending at the beginning of the quarter	0					
	Received during the quarter	23					
	Disposed of during the quarter	23					
	Remaining unresolved at the end of the quarter	0					

SEGMENT WISE REVENUE, RESULTS AND CAPITAL EMPLOYED					
		Quarter Ended			
	PARTICULARS	30/06/2013	31/03/2013	30/06/2012	31/03/2013
		Unaudited	Unaudited	Unaudited	Audited
1	SEGMENT REVENUE :-				
	a) Manufaturing (CRAMS)	10,688.52	7,061.44	6,514.95	24,456.23
	b) Services (DDDSS)	178.43	408.93	537.77	1,332.24
	c) Research & Development	-	-	-	-
	Net Sales from Operations	10,866.95	7,470.37	7,052.72	25,788.47
2	SEGMENT RESULTS :-				
	Profit/(Loss) before tax and interest:				
	a) Manufaturing (CRAMS)	5,179.70	2,355.82	2,494.37	9,176.71
	b) Services (DDDSS)	15.83	41.76	231.20	370.00
	c) Research & Development	(793.87)	(982.12)	(874.68)	(3,469.32)
	TOTAL	4,401.66	1,415.46	1,850.89	6,077.39
Less:	i) Interest	217.43	172.97	298.14	1,174.34
	ii) Other Un-allocable exps net off un-allocable Income	94.04	314.14	671.73	1,617.81
	Total Profit Before Tax	4,090.19	928.35	881.02	3,285.24
3	CAPITAL EMPLOYED				
	(Segment Assets - Segment Liabilities)				
	a) Manufaturing (CRAMS)	17,627.07	12,823.28	11,483.10	12,686.86
	b) Services (DDDSS)	3,286.00	3,053.52	3,131.68	3,221.44
	c) Research & Development	2,684.65	2,412.64	2,525.28	2,412.64
	d) Net assets which are not segmented and used commonly	787.01	3,574.87	1,564.05	3,543.37
	TOTAL	24,384.73	21,864.31	18,704.11	21,864.31

Notes: 1) The above audited results were approved and taken on record at the Board of Directors' meeting held on 13th Aug '13

2) Previous years figures have been regrouped / reclassified whenever necessary.

3) The figures of the 4th qtr 2012-13 are the balancing figures between audited figures inrespect of full year and unaudited declared upto 3 rd qtr ending.
4) Suven Nishtaa pharma pvt ltd, the 100% subsidary, has been merged wef 1 st Jan 2012 and accordingly the results have been prepared. Hence the current quarter figures are not comparable with the previous corresponding quarter figures.
5) The light of the data successful to the the successful to the the the previous corresponding quarter figures.

5) The limited review report has been completed by the Statutary Auditors.

For SUVEN LIFE SCIENCES LTD

VENKAT JASTI Chairman & CEO Place : Hyderabad Date : 13th August 2013

We Deliver